No headlines found.
PRNewswire (Thu, 10-Oct 1:28 PM ET)
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Globe Newswire (Tue, 8-Oct 7:30 AM ET)
Globe Newswire (Mon, 30-Sep 7:30 AM ET)
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Globe Newswire (Fri, 20-Sep 7:30 AM ET)
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Globe Newswire (Tue, 17-Sep 4:05 PM ET)
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Globe Newswire (Thu, 15-Aug 7:00 AM ET)
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
Globe Newswire (Wed, 14-Aug 4:30 PM ET)
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Traws Pharma trades on the NASDAQ stock market under the symbol TRAW.
As of October 31, 2024, TRAW stock price climbed to $5.04 with 1,275 million shares trading.
TRAW has a beta of 0.30, meaning it tends to be less sensitive to market movements. TRAW has a correlation of 0.00 to the broad based SPY ETF.
TRAW has a market cap of $15.25 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that TRAW belongs to (by Net Assets): VTI, VXF.
TRAW support price is $4.61 and resistance is $5.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TRAW shares will trade within this expected range on the day.